Cannabis Was Medicine. Now the Proof Is Catching Up, ft. Joel Stanley and Dr. Marcel Bonn-Miller

The cannabis industry convinced the world it had a medicine before the science caught up. Now the science is here, and almost no one is paying attention. CBD is not a panacea. When Charlotte's Web opened hearts and minds, the messaging of what it could do ran years ahead of what the data could actually support. That gap created a backlash the legitimate medical thesis didn't deserve. What's left on the other side of the green rush is a near-complete forgetting of the reason this industry started in the first place. The medicine. Now the infrastructure to prove it is finally in place. Standardized genetics. Reproducible extraction. Full compound characterization. An FDA botanical drug pathway that has existed since 2016 that most investors have never heard of. Organic medicine versus synthetic single-molecule will be a real choice at the pharmacy counter sooner than most people expect. The foundational work is already here. This week we sit down with Joel Stanley and Dr. Marcel Bonn-Miller: Botanical drugs vs. supplements 6,000 compounds, one drug Novel compounds nobody has named yet Chapters 00:00 Why Medical Validation Remains a Challenge for Cannabis 00:12 The FDA Approval Process for Plant-Based Medicines 01:03 Historical Market Dynamics and Their Impact on Cannabis Perception 02:48 Removing the Veil: How Science Can Validate Cannabinoid Therapies 03:15 The Complexity of Plant Molecules and Real-World Evidence 06:20 Focus in Drug Development: The Case of Autism Spectrum Disorder 07:10 The Impact of Charlotte's Web and Media Hype 08:52 Balancing Hype and Reality in Cannabinoid Medicine 10:01 Legitimization of Cannabis Research in Academia 12:10 The Evolution of Cannabis Research and Acceptance 13:54 The Future of Botanical Medicine and Academic Research 16:15 The Long Road of Drug Development for Cannabis-Based Medicines 20:50 Introducing AJA-001: A Botanical Drug for Autism 22:44 Standardization and Characterization of Botanical Drugs 24:01 Partnerships and Funding in Botanical Drug Development 24:40 Challenges of Multi-Compound Botanical Drugs 27:28 Reproducibility and Quality Control in Botanical Manufacturing 29:06 FDA Pathways for Botanical Drugs and New Chemical Entities 34:29 Identifying and Characterizing Thousands of Plant Compounds 39:48 The Role of AI and Supercomputing in Drug Discovery 41:11 Balancing Exploration and Focus in Botanical Research 44:38 What the World Will Understand About Cannabinoids in 10 Years 47:24 The Promise of Botanical Medicine Over Single Molecule Drugs Guest Links: AJNA Biosciences Websitehttps://ajnabiosciences.com/ AJNA Biosciences LinkedInhttps://www.linkedin.com/company/ajna-biosciences/posts/?feedView=all AJNA Biosciences Instagram @ajnabiosciences Charlotte’s Web Websitehttps://www.charlottesweb.com/ Charlotte’s Web LinkedInhttps://www.linkedin.com/company/charlottesweb/posts/?feedView=all Charlotte’s Web Instagram @charlotteswebcbd Joel Stanley LinkedInhttps://www.linkedin.com/in/joel-stanley-2885116b/ Joel Stanley Instagram @joel.stanley Dr. Marcel Bonn-Miller LinkedInhttps://www.linkedin.com/in/marcel-bonn-miller-897a581/ Our Links: Bryan Fields on Twitter Kellan Finney on Twitter The Dime on Twitter Extraction Teams: Want to cut costs and get more out of every run? Unlock hidden revenue by extracting more from the same input—with Newton Insights. At Eighth Revolution (8th Rev), we provide services from capital to cannabinoid and everything in between in the cannabinoid industry. The Dime is a top 5% most shared  global podcast The Dime is a top 10 Cannabis Podcast  The Dime has a New Website. Shhhh its not finished. 🎥 YouTube:  The Dime 📸 Instagram:  The Dime https://www.newton-insights.com/ Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.